Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$211.80 -0.8%	$189.84	$153.58 ▼ $218.66	$373.91B	0.61	6.16 million shs	6.14 million shs
BMY Bristol-Myers Squibb	$59.83 -2.7%	$57.69	$39.35 ▼ $63.33	$121.40B	0.43	11.67 million shs	10.81 million shs
JNJ Johnson & Johnson	$162.93 -1.8%	$154.23	$140.68 ▼ $169.99	$392.27B	0.47	7.09 million shs	8.01 million shs
MRK Merck & Co., Inc.	$93.44 -1.4%	$93.75	$81.04 ▼ $134.63	$236.04B	0.35	10.09 million shs	11.89 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.89%	+0.09%	+11.30%	+22.32%	+17.10%
BMY Bristol-Myers Squibb	-2.68%	-0.03%	+7.80%	+6.30%	+9.97%
JNJ Johnson & Johnson	-1.77%	-1.39%	+5.65%	+11.42%	+0.12%
MRK Merck & Co., Inc.	-1.28%	+0.24%	+8.01%	-7.73%	-23.82%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.6699 of 5 stars	2.4	5.0	3.3	3.9	3.0	2.5	1.3
BMY Bristol-Myers Squibb	4.3362 of 5 stars	2.2	3.0	4.2	4.0	3.5	3.3	0.0
JNJ Johnson & Johnson	4.4487 of 5 stars	2.3	3.0	4.2	3.9	2.9	3.3	0.6
MRK Merck & Co., Inc.	4.9993 of 5 stars	4.3	3.0	4.2	3.9	3.3	3.3	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$211.45	-0.17% Downside
BMY Bristol-Myers Squibb	2.32	Hold	$57.86	-3.29% Downside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	5.16% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	25.33% Upside

Current Analyst Ratings Breakdown

Latest BMY, JNJ, ABBV, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/10/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00
3/5/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$159.00 ➝ $171.00
3/4/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$200.00 ➝ $223.00
2/19/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
2/18/2025	MRK Merck & Co., Inc.	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$128.00 ➝ $105.00
2/12/2025	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $115.00
2/10/2025	MRK Merck & Co., Inc.	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$121.00 ➝ $100.00
2/10/2025	MRK Merck & Co., Inc.	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$121.00 ➝ $100.00
2/7/2025	BMY Bristol-Myers Squibb	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $62.00
2/5/2025	MRK Merck & Co., Inc.	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$118.00 ➝ $112.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.64	$15.65 per share	13.53	$1.90 per share	111.48
BMY Bristol-Myers Squibb	$48.30B	2.51	$6.31 per share	9.48	$8.08 per share	7.40
JNJ Johnson & Johnson	$88.82B	4.42	$13.39 per share	12.17	$29.69 per share	5.49
MRK Merck & Co., Inc.	$64.17B	3.68	$3.24 per share	28.82	$14.85 per share	6.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	88.25	15.15	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	9.82	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	24.50	14.72	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	13.88	9.44	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)

Latest BMY, JNJ, ABBV, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.10%	+6.04%	273.33%	53 Years
BMY Bristol-Myers Squibb	$2.48	4.15%	+6.38%	N/A	17 Years
JNJ Johnson & Johnson	$4.96	3.04%	+5.43%	74.59%	63 Years
MRK Merck & Co., Inc.	$3.24	3.47%	+5.73%	48.14%	14 Years

Latest BMY, JNJ, ABBV, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/14/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
BMY Bristol-Myers Squibb	2.90	1.25	1.15
JNJ Johnson & Johnson	0.43	1.11	0.86
MRK Merck & Co., Inc.	0.79	1.36	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol-Myers Squibb	76.41%
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol-Myers Squibb	0.09%
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
BMY Bristol-Myers Squibb	34,100	2.03 billion	2.03 billion	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable

BMY, JNJ, ABBV, and MRK Headlines

Recent News About These Companies

Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note

March 13 at 12:06 AM | msn.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc. (MRK) Shareholders

March 12 at 5:45 PM | accessnewswire.com

Merck & Co., Inc. (NYSE:MRK) Trading Down 0.9% - What's Next?

March 12 at 3:32 PM | marketbeat.com

Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds

March 12 at 2:57 PM | insidermonkey.com

Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025

March 12 at 2:03 PM | finance.yahoo.com

Merck & Co., Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

March 12 at 1:45 PM | accessnewswire.com

Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48

March 12 at 11:26 AM | businesswire.com

Merck & Co., Inc. (MRK): Among Dobermans of the Dow to Buy

March 12 at 11:15 AM | insidermonkey.com

Avantax Advisory Services Inc. Purchases 4,518 Shares of Merck & Co., Inc. (NYSE:MRK)

March 12 at 7:51 AM | marketbeat.com

Securian Asset Management Inc. Cuts Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

March 12 at 7:34 AM | marketbeat.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK

March 12 at 7:25 AM | accessnewswire.com

Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Great Lakes Advisors LLC

March 12 at 7:22 AM | marketbeat.com

MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Merck & Co., Inc. to Contact the Firm Today!

March 12 at 7:00 AM | accessnewswire.com

Merck & Co., Inc. (NYSE:MRK) Stock Position Increased by Sequoia Financial Advisors LLC

March 12 at 6:38 AM | marketbeat.com

Saturna Capital Corp Has $94.06 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

March 12 at 6:30 AM | marketbeat.com

Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky

March 12 at 5:45 AM | prnewswire.com

Pzena Investment Management LLC Buys Shares of 2,898 Merck & Co., Inc. (NYSE:MRK)

March 12 at 5:12 AM | marketbeat.com

Edgestream Partners L.P. Reduces Stock Position in Merck & Co., Inc. (NYSE:MRK)

March 12 at 4:00 AM | marketbeat.com

Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

March 11 at 10:30 PM | accessnewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK

March 11 at 10:14 PM | accessnewswire.com

Merck (NYSE:MRK) Unveils US$1 Billion Durham Facility For Advanced Vaccine Manufacturing Expansion

March 11 at 6:00 PM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, JNJ, ABBV, and MRK Company Descriptions

AbbVie NYSE:ABBV

$211.80 -1.79 (-0.84%)

Closing price 03/12/2025 03:58 PM Eastern

Extended Trading

$211.89 +0.09 (+0.04%)

As of 03/12/2025 07:40 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol-Myers Squibb NYSE:BMY

$59.82 -1.69 (-2.74%)

Closing price 03/12/2025 03:59 PM Eastern

Extended Trading

$59.83 +0.00 (+0.01%)

As of 03/12/2025 07:43 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson NYSE:JNJ

$162.93 -2.93 (-1.77%)

Closing price 03/12/2025 03:59 PM Eastern

Extended Trading

$163.10 +0.17 (+0.10%)

As of 03/12/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$93.44 -1.29 (-1.36%)

Closing price 03/12/2025 03:58 PM Eastern

Extended Trading

$93.60 +0.16 (+0.17%)

As of 03/12/2025 07:42 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time